Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutations.

Blood cancer journal - 15 Mar 2025

Fiskus Warren, Mill Christopher P, Piel Jessica, Collins Mike, Hentemann Murphy, Cuglievan Branko, Birdwell Christine E, Das Kaberi, Hou Hanxi, Davis John A, Jain Antrix, Malovannaya Anna, Kadia Tapan M, Daver Naval, Sasaki Koji, Takahashi Koichi, Hammond Danielle, Reville Patrick K, Flores Lauren B, Loghavi Sanam, Su Xiaoping, DiNardo Courtney D, Bhalla Kapil N

Abstract excerpt

Although treatment with standard frontline therapies, including a FLT3 inhibitor (FLT3i) reduces AML burden and achieves clinical remissions, most patients with AML with FLT3 mutation relapse due to therapy-resistant stem/progenitor cells. The core ATPases, BRG1 (SMARCA4) and BRM (SMARCA2) of the canonical (c) BAF (BRG1/BRM-associated factor) complex is a dependency in AML cells, including those harboring FLT3...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Line, Tumor

Share to DNA Helicases

Share to fms-Like Tyrosine Kinase 3

Share to Leukemia, Myeloid, Acute

Share to Nuclear Proteins

Share to Protein Kinase Inhibitors

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 40089460
DOI: 10.1038/s41408-025-01251-7
PMCID: PMC11910597

Genes

FLT3
SMARCA2
SMARCA4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutations.PMID 40089460Read ↗

BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitorSemantic proximity Read ↗

BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitorSemantic proximity Read ↗

Mechanism of response to FHD-286 and decitabine combination in patients with advanced myeloid malignanciesSemantic proximity Read ↗

Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199.Semantic proximity Read ↗

Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cellsSemantic proximity Read ↗

Exquisite Sensitivity to Dual BRG1/BRM ATPase Inhibitors Reveals Broad SWI/SNF Dependencies in Acute Myeloid LeukemiaSemantic proximity Read ↗

Induction of AML cell differentiation using HOXA9/DNA binding inhibitors as a potential therapeutic option for HOXA9‐dependent AMLSemantic proximity Read ↗

Side-by-side comparison of BH3-mimetics identifies MCL-1 as a key therapeutic target in AMLSemantic proximity Read ↗

Smac mimetic induces cell death in a large proportion of primary acute myeloid leukemia samples, which correlates with defined molecular markers.Semantic proximity Read ↗

BH3-only protein Bim more critical than Puma in tyrosine kinase inhibitor-induced apoptosis of human leukemic cells and transduced hematopoietic progenitors carrying oncogenic FLT3.Semantic proximity Read ↗

Synergistic Targeting of AML Stem/Progenitor Cells With IAP Antagonist Birinapant and Demethylating AgentsSemantic proximity Read ↗

HDZ-740, a Potent FLT3 Inhibitor to Overcome FLT3 Mutations of Acute Myeloid LeukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.